source
- Novartis halts ALS drug VHB937 after phase 2 trial fails to meet endpointsNovartis announced it is stopping development of its ALS candidate VHB937 after the phase 2 Astrals trial did not meet its primary or secondary endpoints. The study enrolled 251 patients with earl…
- Skyhawk reports functional gains in Huntington's disease trial of RNA-splicing pillSkyhawk Therapeutics, a Boston biotech backed by Fidelity, released final data from a small mid-stage trial of its once-daily RNA-splicing pill for Huntington's disease. After 15 months, patients…